ArriVent BioPharma (AVBP) Stock Price, News & Analysis

Company Overview

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.

ArriVent’s lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations. Furmonertinib has been approved in China for certain EGFR-mutated non-small cell lung cancer indications and is being evaluated by ArriVent in additional patient populations and geographies.

The company obtained rights to develop and commercialize furmonertinib outside Greater China through a partnership with Allist Pharmaceuticals. ArriVent is headquartered in the United States and is advancing its programs through clinical trials intended to support potential regulatory submissions in the United States and other international markets. Its pipeline and development strategy are centered on targeted oncology therapies for patients whose tumors have actionable genetic alterations.

Key Stats

• Today's Range: $27.02 to $28.70
• 50-Day Range: $27.65 to $31.49
• 52-Week Range: $17.00 to $35.83
• Volume: 317,589 shs
• Average Volume: 525,022 shs
• Market Capitalization: $1.40 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.86
• Consensus Rating: Moderate Buy

ArriVent BioPharma Stock Analysis - MarketRank™

ArriVent BioPharma scored higher than 54% of companies evaluated by MarketBeat, and ranked 447th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ArriVent BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

ArriVent BioPharma has a consensus price target of $44.86, representing about 60.5% upside from its current price of $27.96.

Amount of Analyst Coverage

ArriVent BioPharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ArriVent BioPharma are expected to grow in the coming year, from ($4.11) to ($4.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ArriVent BioPharma is -7.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ArriVent BioPharma is -7.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ArriVent BioPharma has a P/B Ratio of 3.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.45% of the float of ArriVent BioPharma has been sold short.

Short Interest Ratio / Days to Cover

ArriVent BioPharma has a short interest ratio ("days to cover") of 17.69, which indicates bearish sentiment.

Change versus previous month

Short interest in ArriVent BioPharma has recently increased by 0.86%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ArriVent BioPharma does not currently pay a dividend.

Dividend Growth

ArriVent BioPharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

ArriVent BioPharma has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Healthcare companies.

MarketBeat Follows

1 people have added ArriVent BioPharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ArriVent BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.58% of the stock of ArriVent BioPharma is held by insiders.

Percentage Held by Institutions

9.48% of the stock of ArriVent BioPharma is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AVBP
• Previous Symbol: NASDAQ:AVBP
• CIK: 1868279
• Web: www.arrivent.com
• Phone: 628-277-4836
• Fax: N/A
• Employees: 77
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ArriVent BioPharma: $44.86
• High Price Target: $50.00
• Low Price Target: $40.00
• Potential Upside/Downside: +57.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$166.31 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -50.26%
• Return on Assets: -46.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.16
• Quick Ratio: 14.16

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.44 per share
• Price / Book: 3.82

Miscellaneous

• Outstanding Shares: 49,310,000
• Free Float: 45,077,000
• Market Cap: $1.40 billion
• Optionable: N/A
• Beta: 1.34